Literature DB >> 15030116

Breast cancer patients should not live without a HER-2/neu tissue result--but how safe can they live with it?

Diana Lüftner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15030116     DOI： 10.1007/BF03040416

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN： 0043-5325            Impact factor:   2.275


× No keyword cloud information.
  12 in total

1.  Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard.

Authors:  S Wang; M H Saboorian; E P Frenkel; B B Haley; M T Siddiqui; S Gokaslan; F H Wians; L Hynan; R Ashfaq
Journal:  Am J Clin Pathol       Date:  2001-10       Impact factor: 2.493

Review 2.  The role of HER-2 expression in predicting response to therapy in breast cancer.

Authors:  R Mass
Journal:  Semin Oncol       Date:  2000-12       Impact factor: 4.929

Review 3.  Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2).

Authors:  M J van de Vijver
Journal:  Eur J Cancer       Date:  2001-01       Impact factor: 9.162

4.  Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization.

Authors:  A Lebeau; D Deimling; C Kaltz; A Sendelhofert; A Iff; B Luthardt; M Untch; U Löhrs
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

5.  Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells.

Authors:  J Codony-Servat; J Albanell; J C Lopez-Talavera; J Arribas; J Baselga
Journal:  Cancer Res       Date:  1999-03-15       Impact factor: 12.701

6.  Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer.

Authors:  R Simon; A Nocito; T Hübscher; C Bucher; J Torhorst; P Schraml; L Bubendorf; M M Mihatsch; H Moch; K Wilber; A Schötzau; J Kononen; G Sauter
Journal:  J Natl Cancer Inst       Date:  2001-08-01       Impact factor: 13.506

7.  ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients.

Authors:  S Braun; G Schlimok; I Heumos; G Schaller; L Riethdorf; G Riethmüller; K Pantel
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

8.  Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study.

Authors:  M Bilous; C Ades; J Armes; J Bishop; R Brown; B Cooke; M Cummings; G Farshid; A Field; A Morey; P McKenzie; W Raymond; P Robbins; L Tan
Journal:  Breast       Date:  2003-04       Impact factor: 4.380

9.  Discordant results obtained for different methods of HER-2/neu testing in breast cancer--a question of standardization, automation and timing.

Authors:  D Luftner; P Henschke; A Kafka; I Anagnostopoulos; K Wiechen; R Geppert; H Stein; K D Wernecke; R Kreienberg; K Possinger
Journal:  Int J Biol Markers       Date:  2004 Jan-Mar       Impact factor: 3.248

10.  The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma.

Authors:  S A Rasbridge; C E Gillett; A M Seymour; K Patel; M A Richards; R D Rubens; R R Millis
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.